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Abstract 
This study aims to evaluate the efficacy of Trial-Based Cognitive Therapy (TBCT), a new 
cognitive behavioral therapy approach, for generalized SAD (GSAD) in a population with 
high rates of comorbidity, especially depression. This two-arm randomized clinical trial 
included 39 adults (TBCT = 18; Waitlist group = 21) diagnosed with GSAD. The TBCT 
group received 16 weekly individual sessions. The participants were evaluated at pre- and 
post-test. There were reductions in social anxiety, social avoidance, and depression in the 
TBCT group, all associated with a large effect size. There were no differences between pre- 
and post-test scores in the waitlist group. Results also showed that comorbidity significantly 
moderated treatment efficacy. Treated patients with comorbid conditions showed greater 
reductions in social anxiety symptoms than those with SAD only. TBCT was effective in 
reducing social anxiety and depression symptoms, and it seems to be particularly efficacious 
for  patients with comorbidity. 
Keywords: Trial-Based Cognitive Therapy; Social Anxiety Disorder; Depression; 
Comorbidity; Randomized Clinical Trial. 
 
Social anxiety disorder (SAD) is characterized by intense fear of social situations in 
which individuals could be judged by other people. A central feature of SAD is fear of 
negative evaluation, which contributes to the avoidance of social situations (American 
Psychiatric Association, 2013). The condition carries a high disease burden and is one of the 
most common psychiatric disorders (Martin, 2003; Kessler et al., 2005). Despite the different 
prevalence rates found in the literature, most likely related to distinct assessment methods 
used across studies, SAD has a high lifetime prevalence. Its prevalence varies from 6.65% in 
European countries (Fehm, Pelissolo, Furmark, & Wittchen, 2005) to 12.1% in the United 
States (Kessler et al., 2005). A similar lifetime prevalence is observed in Brazilian 
community samples with a prevalence rate higher than 11% (Baptista, et al., 2012; Vorcaro, 
Rocha, Uchoa, & Lima-Costa, 2004). SAD is a chronic and impairing condition (Fehm at al., 
2005; Martin, 2003), and is associated with a significantly reduced quality of life (e.g., 
Wittchen & Beloch, 1996; Wong, Sarver, & Beidel, 2012). Not only does SAD interfere with 
social functioning (e.g., Wittchen & Beloch, 1996; Ghaedi, Tavoli, Bakhtiari, Melyani, & 
Sahragard, 2010) but also with occupational (e.g., Wittchen & Beloch, 1996) and academic 
performance (e.g., Baptista et al., 2012, Stein & Kean, 2000).  
Comorbid disorders are the rule rather than the exception for SAD, with major 
depressive disorder being frequently associated with social anxiety disorder (Klemanski, 
Curtiss, McLaughlin, & Nolen-Hoeksema, in press; Ohayon & Schatzberg, 2010). SAD is a 
significant risk factor for the subsequent occurrence of depressive symptoms, with anxiety 
onset typically preceding that of depression (Kessler, Stang, Wittchen, Stein, & Walters, 
1999). Furthermore, the combination of the two disorders has been associated with more 
severe suffering and impairment (Dalrymple & Zimmerman, 2007), making it to be difficult 
to treat (Belzer & Schneier, 2004). Notably, research has shown that avoidance mediates the 
relationship between social anxiety and depressive symptoms, suggesting that depression 
may be more likely due to behavioral avoidance, a key symptom of SAD (Moitra, Herbert, & 
Forman, 2008).  
Although pharmacotherapy is effective for SAD (Curtiss, Andrews, Davis, Smits, & 
Hofmann, 2017), cognitive behavioral therapy (CBT) is considered the gold standard 
treatment. Many protocols have been developed to successfully treat this condition (Hofmann 
& Otto, 2008). Several randomized clinical trials corroborate the efficacy of CBT for SAD 
(Barkowski et al., 2016; Hofmann et al., 2013; Hofmann & Smits, 2008; Ponniah & Hollon, 
2006; Otte, 2011), with a mean effect size of .70 (Acaturk, Cuijpers, Van Straten, & De 
Graaf, 2009). Even though the findings show that exposure interventions and cognitive 
techniques significantly reduce social phobia symptoms (Barkowski et al., 2016; Federoff & 
Taylor, 2001; Feske & Chambless, 1995; Gould, 1997; Otte, 2011; Taylor, 1996), the 
emphasis on changing cognitions has been shown to be more effective in SAD treatment in 
individual format (Mörtberg, Clark, Sundin, & Wistedt, 2007; Stangier, Heidenreich, Peitz, 
Lauterbach, & Clark, 2003). Some findings suggest that individual cognitive therapy is more 
effective than exposure (Clark et al., 2006; Mayo-Wilson et al., 2014; Ougrin, 2011) and 
some forms of group CBT (Mörtberg et al., 2007), which highlight the importance of 
targeting cognitions in SAD treatment. Indeed, current literature has suggested that cognitive 
factors function as maintenance factors in SAD (Hofmann, 2007). 
Despite the well-established efficacy of CBT as a gold treatment for SAD, a 
significant proportion of patients do not improve after treatment. Many patients remain 
symptomatic after undergoing CBT (Hofmann, 2007), with 40% of patients requesting 
additional treatment within a year after having received CBT (Gilian et al., 1984), and just 
48% of the patients being classified as responders after the treatment (Heimberg et al., 1998). 
Research shows that CBT for comorbid SAD and depression reduces anxiety symptoms, yet 
depression symptoms remain elevated (Joormann, Kosfelder, & Schulte, 2005). Also, patients 
with comorbid diagnoses of SAD and depression drop out more frequently than patients with 
depression alone (Brown et al., 1996). These findings underscore the importance of 
improving the current treatments in the field. 
Trial-Based Cognitive Therapy (TBCT) is a CBT intervention that was recently 
developed in Brazil at the beginning of the 2000s. TBCT has its foundation in the cognitive-
behavioral approach. Like CBT, TBCT contains psycho-education, cognitive restructuring, 
and exposure along with homework assignments. However, this variation of the CBT 
approach has its own specific cognitive conceptualization, techniques, and instruments, 
making it a unique intervention (de Oliveira, 2015a; de Oliveira et al., 2015b; Morrison et al., 
2015). 
The Trial is the main TBCT technique and is designed to challenge and restructure 
dysfunctional core beliefs (CBs) using a metaphor with the law in an experiential way. It is a 
structured seven-step approach in which the therapist uses a seven-column worksheet to 
guide the patient through a role-play of a court trial. Inspiration for this technique was found 
in The Trial, a novel wrote by Franz Kafka (Kafka, 1998). In this novel, the main character, 
Joseph K., is arrested, convicted, and executed of a crime of which he had no knowledge. 
Making a parallel with the CBT perspective, de Oliveira (2011) proposes that the self-
accusations correspond to core beliefs (CBs) about the self, and, similar to Joseph K., most 
patients are not aware of these. They commonly react and accept CBs as the truth about 
themselves. Through the Trial, an inquiry is established where the patients become aware of 
their self-accusations (CBs) and, different from Joseph K., have a chance to construct a 
proper defense (de Oliveira, 2011). The Trial incorporates different cognitive behavioral 
techniques, such as examining the evidence and the downward arrow technique, in a unique 
way. An experiential approach is employed using the empty-chair technique (De Oliveira et 
al., 2012), which is widely used in Gestalt therapy (Perls, 1973).  
Preliminary studies support this approach. In 30 patients with different diagnoses, this 
treatment effectively decreased the attachment to the dysfunctional CBs, as well as the 
emotional intensity, during a session (De Oliveira, 2008). In a replication of this study, De 
Oliveira et al. (2012) evaluated the effect of the intervention in 166 patients with different 
diagnoses as well as different comorbidities. Results from this study showed a significant 
reduction in the attachment to dysfunctional CBs and in the emotional intensity. When 
comparing therapists with different levels of experience, there were no differences in 
treatment outcome, indicating that the treatment may be a helpful tool even for clinicians that 
are relatively unfamiliar with it. Another study showed that TBCT was effective for 39 
patients with different diagnoses, substantiating TBCT as a putative transdiagnostic 
intervention (Delavechia et al., 2016). 
In the context of treating SAD, a randomized clinical trial compared TBCT techniques 
and conventional CBT techniques in treating generalized SAD (GSAD). In this study, 36 
GSAD participants were randomly assigned to be treated with either the TBCT technique or 
traditional cognitive techniques in 12 individual sessions. Both treatments followed the same 
protocol in the first five sessions, differing, however, from sessions 6 through 12. The results 
showed that TBCT is at least as efficacious as conventional CBT techniques in reducing 
social anxiety symptoms and improving quality of life, and more efficacious than CBT in 
reducing fear of negative evaluation, social avoidance, and distress (De Oliveira et al., 2012b; 
Powell et al., 2013). 
 The specific focus of TBCT on promoting in cognitive changes may make this a 
promising new approach to the treatment of SAD, since the literature shows that treatments 
focusing on cognitive change are effective in treating this condition (Clark et al., 2006; 
Mörtberg, Clark, Sundin, & Wistedt, 2007; Ougrin, 2011). In addition, the literature has 
shown that this new CBT technique is effective not only for SAD, but for different 
psychiatric conditions as well (De Oliveira, 2008; De Oliveira et al., 2012a; De Oliveira et 
al., 2012b; Delavechia et al., 2016; Powell et al., 2013). However, further investigation is 
needed to better demonstrate the efficacy of TBCT as a treatment for SAD and other 
disorders. 
The aim of this study is to evaluate the efficacy of TBCT for generalized Social 
Anxiety Disorder in a population with high rates of comorbidity, especially depression. As 
the CBT literature shows that cognitive change is a potent factor for SAD treatment, we 
hypothesize that participants who received TBCT will experience reduced social anxiety 
symptoms compared to participants randomized to a control condition, as this new CBT 
approach uses different techniques to promote cognitive restructuring. In addition, we 
hypothesize that patients treated with TBCT will have reduced comorbid depressive 
symptoms, which would be consistent with prior literature supporting TBCT as a 
transdiagnostic intervention. As the literature shows that the presence of comorbidity, 
especially depression, affects the treatment outcome for SAD, this study also aims to examine 
comorbidity as a hypothesized treatment moderator on symptom change. As far as we know, 
there have been no studies evaluating the application of the entire TBCT protocol treatment 
for individuals diagnosed with SAD and other conditions. Thus, this is the first randomized 
clinical trial comparing the effect of a TBCT intervention to a waitlist condition for SAD.  
Method 
Design  
 This is a two-arm randomized clinical trial comparing TBCT and a waitlist control 
condition (delayed intervention) for treatment of generalized SAD. An independent 
researcher not participating in the study provided the randomization schedule of the 
participants between the two conditions. The treatment was delivered in sixteen 1.5 hour 
sessions using the individual format during a total span of four to five months. The treatment 
was administered by the main researcher of this study, and followed the therapist manual for 
TBCT (De Oliveira, 2015) and a specifically tailored treatment for SAD (De Oliveira et al., 
2012b; Powell et al., 2013). The therapist is a clinical psychologist with five years of 
experience who attended four TBCT trainings administered by Prof. Dr. Irismar Reis de 
Oliveira, the TBCT founder. The recruitment, selection, and treatment occurred at Ribeirão 
Preto, a southeast city in Brazil. The Institutional Review Board at the Faculty of Philosophy, 
Sciences and Letters at Ribeirão Preto, University of São Paulo, Brazil, approved the study 
(23789213.2.0000.5407). The Brazilian Clinical Trials Registry approved the study (RBR-
98qjbw) as well.  
Participants 
 Participants were recruited from the community via advertisements that were posted 
in public health center areas, interviews on local radio and television about the research, and 
the marketing channels of the University of São Paulo. Participants were enrolled in the study 
between August 20, 2014, and December 18, 2015. Participants interested in enrolling the 
study contacted LaPICC-USP (Cognitive Behavioral Research and Laboratory – University 
of São Paulo) through e-mail or telephone. Those who were between 18 to 45 years old were 
invited for a diagnostic interview with clinical psychologists from LaPICC-USP. Those 
researchers are CBT psychologists who have a minimum of five years of experience in using 
structured clinical interviews and diagnostic assessments. They underwent CBT training for 
one and half years. Of the 158 participants who expressed interest to participate, 124 were 
interviewed, of whom 62 met inclusion criteria and were eligible. They were randomly 
assigned by an independent researcher to TBCT treatment (n = 27) or Waitlist control (n = 
35). Of the 27 participants who were assigned to TBCT treatment, 9 were excluded from the 
analysis for the following reasons: 1 participant withdrew after the random allocation, 1 
participant was excluded after the first session for receiving other psychotherapy 
simultaneously, and 7 withdrew before finishing half of the treatment (these participants 
received less than 7 sessions). Thus, all the 18 patients in the TBCT group included in the 
analyses received at least 85% of the treatment (1 patient received 14 sessions and 17 patients 
received 16 sessions). Of the 35 participants who were assigned to Waitlist control, 14 were 
excluded from the analysis for the following reasons: 1 participant was excluded for taking 
anxiolytic medication during the pre- and post- test interval, and 13 withdrew after the pre-
test assessment. Thus, the TBCT group has 18 participants, and the Waitlist control 21 
participants. Figure 1 depicts the progress of participants in the study. 
 The mean age of the sample was 29.56 (SD = 5.52). The majority of the sample was 
female (n = 29), had a college degree (n = 19), and 56.4% of participants (n = 22) were 
employed. Diagnostic interviews revealed that 24 participants had at least one additional 
comorbid conditino, with depression being the most common additional diagnosis (n = 16). 
In the TBCT group, 4 participants received only a GSAD diagnosis, and 14 had at least one 
additional comorbid condition. In the Wait list group, 3 participants had only GSAD, and 18 
had at least one additional secondary diagnosis. Thus, only 7 participants presented with 
GSAD as the unique diagnosis. Regarding psychotropic medication intake, 28.2% of the 
patients (n = 11) were receiving a stable dose of anxiolytic or antidepressant medication 
before the beginning of the study (71.8% did not use this type of medication), and 23% (n = 
9) had already received a previous SAD diagnosis. Participants in the group that received 
TBCT treatment differed from the Waitlist control regarding psychotropic medication intake 
and previous SAD diagnosis. There were more patients in the treated group taking this type 
of medication [χ²(1) = 7.84, P = .005] and with a previous SAD diagnosis [χ²(1) = 4.70, P 
= .03]. This may indicate that the patients randomized to the TBCT group might have a more 
chronic and severe SAD, which may affect the treatment response. Thus, psychotropic 
medication intake and previous SAD diagnosis were entered as covariates in subsequent 
analyses, as well as the other demographic variables. No other group differences were 
observed in the demographic variables, nor were there any differences present at between 
assessment measures at baseline. Table 1 shows the sample characteristics.  
Assessment 
 We used the SAD module of the Structured Clinical Interview for DSM-IV – 
Research Version (SCID-I/P 2.0), developed by First, Spitzer, Gibbon & Williams (2002) to 
determine SAD diagnosis. In addition, we used the clinician version of the SCID (SCID-CV) 
developed by First, Spitzer, Gibbon & Williams (1996) to determine other psychiatric 
diagnoses. These are gold-standard structured clinical interviews based on the DSM-IV.  
 The Social Phobia inventory (SPIN) was used as the primary outcome measure. It is a 
17-item self-report Likert scale that measures physiological, emotional, and behavioral 
symptoms of SAD (Conner et al., 2000). The SPIN discriminates socially anxious people 
from normal controls using a 19 cut-off point and is a reliable measure for evaluating 
treatment changes in social anxiety symptoms (Conner et al., 2000; Osório, Crippa & 
Loureiro, 2009). Additional SAD measures included the Fear of Negative Evaluation (FNE) 
and the Social Avoidance and Distress Scale (SADS), which evaluate central social anxiety 
characteristics: fear of negative evaluation, avoidance behavior, and the distress related to 
entering social situations (Watson & Friend, 1969). The depression measure included the 
Beck Depression Inventory (BDI-II) (Beck, Steer & Brown, 1996), which was used as 
secondary outcome measure. All instruments were utilized at intake (baseline/pre-test) and at 
post-test (2 weeks after the last session), with exception of the SCID-IV which was used only 
at intake to diagnostic purpose.  
Study criteria 
 We used the following inclusion criteria: age ranging between 18 and 45 years old; 
diagnosis of generalized Social Anxiety Disorder using DSM-IV criteria; scores higher or 
equal to 19 points on the SPIN; and ability to read and sign the informed consent. Exclusion 
criteria included psychotic symptoms, high suicide risk, diagnosis of Post-Traumatic Stress 
Disorder, and SAD diagnosis secondary to other disorders according to SCID-IV. 
Furthermore, we excluded patients presently in psychotherapy who did not want to stop their 
concurrent treatment or who were taking psychotropic medication that was not stabilized for 
at least one month before the assessment.  
Treatment  
 The patients randomized to the treatment group received 16 individual sessions of 
TBCT. Each session lasted one and a half hours. Session 1 covered a psychoeducation 
concerning anxiety, SAD, and the treatment overview. Session 2 provided a discussion about 
the cognitive model, automatic thoughts and cognitive distortions, using the TBCT case 
conceptualization diagram. In session 3 patients were introduced to the Cognitive Distortions 
Questionnaire, a TBCT instrument that helps the patients be aware of cognitive distortions 
that occur during the week. The patients filled this questionnaire from session 3 onward. The 
main agenda of sessions 4 and 5 was to promote a restructuring of dysfunctional automatic 
thoughts using the Intrapersonal Thought Record, a TBCT thought record. Sessions 6 to 8 
were used to promote restructuring of the conditional beliefs/rules that are normally related to 
safety behaviors, such as avoidance. The Consensual Role-Play technique was used during 
these sessions to target both conditional beliefs and avoidance behavior. This TBCT 
technique is designed to help patients to understand and resolve their approach / avoidance 
conflict: the ambivalence towards their behaviors that they would like to do (approach), but 
are still afraid of (avoidance). 
During sessions 9 to 13 dysfunctional core beliefs were restructured using the Trial. 
In TBCT it is used to engage patients in a simulation of a court trial. This form of role-play 
helps them to be aware of and evaluate the dysfunctional CBs. In addition, it helps the 
patients to activate and strengthen more functional CBs (De Oliveira, 2007). Sessions 14 and 
15 covered a discussion about metacognition and the patients were involved in the Trial II.  
As in the Trial, the Trial II is another role-play technique that engages the patients in 
a simulation of a court trial to foster awareness of the self-accusatory nature of dysfunctional 
CBs. Finally, session 16 covered relapse prevention and a review of the whole treatment. For 
homework, the patients were encouraged to complete exposures between the sessions and fill 
out the TBCT sheets discussed during the sessions.  
 Data analysis 
 To address our primary hypothesis, a latent change score modelling approach was 
adopted. We chose this approach because it: 1) better handles the dependent nature of 
longitudinal data, 2) can handle missing data with full information maximum likelihood 
estimation (FIML), and 3) can provide fit indices to assist in determining model fit. Such 
analyses invoke a latent variable to estimate change across two individual time points 
(McArdle, 2009). In accordance with the procedures described by Coman et al. (2013), a 
latent change model was specified such that the mean of the latent variable represents the 
difference between the pre-treatment (T1) and post-treatment means (T2). The T2 variable 
was regressed on both the latent change variable and the T1 variable, and both pathways were 
fixed to 1. Furthermore, the pathway from T1 to the latent change score was fixed to 0, which 
indicates stability in changes. If this assumption was not upheld, as indicated by poor model 
fit, then a covariance parameter between T1 and the latent change score was permitted. 
Furthermore, the variance of the latent change score was fixed to 1, and the intercept of the 
T2 was fixed to 0.  
 To estimate a conditional latent change score model, the latent change score was 
regressed on a dummy variable representing treatment condition (1= TBCT, 2= Waitlist). 
Consistent with the hypotheses of the current study, these models were estimated to 
determine whether TBCT resulted in greater changes in social anxiety symptoms and 
depression symptoms relative to the waitlist control. The SPIN and the BDI-II were used to 
assess for symptoms of social anxiety and depression, respectively. Furthermore, we 
examined the interaction effects between treatment condition and some hypothesized 
moderators, such as pre SAD diagnosis and psychotropic medication intake on symptom 
change. All continuous moderators were mean centered to facilitate interpretation and 
mitigate undue collinearity.   
 Missing data were accommodated with full-information maximum likelihood 
estimation. The following fit indices were examined to evaluate global model fit: chi square 
statistic, comparative fit index (CFI), Tucker-Lewis index (TLI), and the root mean squared 
error of approximation (RMSEA). In addition to the presence of a non-significant chi square 
statistic, good model fit was evidenced by CFI and TLI values exceeding .90, as well as 
RMSEA values less than .08 (Hu & Bentler, 1998). The latent change score analyses were 
estimated in R with the latent variable program Lavaan (Rosseel, 2012). For effect size 
estimates, we abided by conventional guidelines for Cohen’s d (i.e., small = 0.30, medium = 
0.50, and large = 0.80) (Cohen, 1988).  
Results 
Pre-treatment to post-treatment and between group differences 
 As indicated in Table 2, TBCT resulted in statistically significant reductions in all 
outcome measures except fear of negative evaluation between pre- and post-treatment 
analysis, and in social anxiety and depression symptoms in ANCOVA, controlling for 
baseline differences and baseline levels of each outcome variable. Consistent with established 
precedent (Cohen, 1988), all of the within and between-group effect sizes were in the large 
range. Individuals in the waitlist control group did not evidence significant change from pre-
treatment to post-treatment, and all of the effect sizes were in the small range. To address 
multiple comparisons, all p-values were submitted to false discovery rate correction.  
Latent change score analyses 
 Results of the latent change score analyses are presented in Table 3. The conditional 
latent change score model for social anxiety symptoms evidenced good fit with a non-
significant chi-square statistic (c2 = 2.54, p = .27), as well as good fit indices (i.e., CFI = 
0.98; TLI = 0.98; and RMSEA = 0.08) (Figure 2). Our primary hypothesis was corroborated, 
as treatment condition significantly predicted the latent change score (g = -22.73, p < .01). 
This suggests that, on average, individuals in the TBCT condition experienced significantly 
greater reductions in social anxiety symptoms relative to waitlist control. Moreover, this 
between group difference was associated with a large effect size (d = 1.53).  
 The original conditional latent change score model for depression symptoms exhibited 
mediocre fit with a significant chi-square statistic (c2 = 12.95, p = .01), as well as poor fit 
indices (i.e., CFI = 0.35; TLI = 0.00; and RMSEA = 0.29). Thus, we permitted a covariance 
parameter between the latent change score and pre-treatment depression symptoms, which 
relaxes the assumption that change across time must be stable. The new model evidenced 
good fit with a non-significant chi-square statistic (c2 = 2.40, p = .30), as well as good fit 
indices (i.e., CFI = 0.97; TLI = 0.93; and RMSEA = 0.07). A chi-square difference test 
comparing the two models was significant (c2D = 14.55, df = 2, p < .01), suggesting that the 
new model exhibits significantly better fit than does the original model. Furthermore, the 
hypothesis for differential efficacy for depression outcome was supported, as treatment 
condition significantly predicted the latent change score (g = -11.15, p < .01). This suggests 
that, on average, individuals in the TBCT condition experienced significantly greater 
reductions in depression symptoms relative to waitlist control. Moreover, this between group 
difference was associated with a large effect size (d = 1.05).i 
 To determine whether demographic and clinical characteristics moderated treatment 
outcome, a number of models including interaction terms were pursued. Results revealed that 
only comorbidity significantly moderated treatment efficacy (g = -11.35, p < .05). 
Specifically, individuals with comorbid conditions evidenced greater reductions in social 
anxiety symptoms (g = -27.64, p < .01) than did those with only social anxiety disorder (g = -
16.29, p < .01). None of the other interaction effects were significant, including age (g = 0.38, 
p = 0.44), gender (g = -5.69, p = 0.35), prior history of a social anxiety disorder diagnosis (g = 
-5.30, p = .95), or psychotropic medication intake (g = -6.86, p = .26). 
Discussion 
 The present study sought to evaluate the efficacy of TBCT for generalized SAD in a 
population with high rates of comorbidity, especially depression. It is the first two-arm 
randomized clinical trial comparing TBCT and a control condition (waitlist group) for the 
treatment of generalized SAD. 
 Consistent with our primary hypothesis, TBCT was effective in reducing social 
anxiety symptoms as the participants in the TBCT group experienced greater reductions in 
SPIN relative to participants in the waitlist condition. Moreover, this between group 
difference was associated with a large effect size (d = 1.53). Moreover, TBCT was effective 
in reducing symptoms of social avoidance and distress as measured by the SADS. It is 
important to note that these symptoms are the cardinal characteristics of social anxiety 
disorder, and the between group difference for these symptoms was associated with a large 
effect size (d = 1.07). Additionally, TBCT was effective in reducing depression symptoms as 
the TBCT participants experienced significantly greater reductions in BDI-II relative to 
waitlist condition. This between group difference was also associated with a large effect size 
(d = 1.05).  
 This study aligns with previous research about the efficacy of CBT on SAD 
symptoms. It is consistent with a recent meta-analysis that evaluated the effect of CBT in 
treating SAD (Acarturk et al., 2009), and recent studies that show that CBT is highly 
effective in treating SAD (Barkowski et al., 2016; Hofmann et al., 2013; Ponniah & Hollon, 
2006; Otte, 2011). That meta-analysis only included randomized clinical trials, and found a 
mean effect size of .70 for SAD measures. Considering the studies that compared the 
treatment with waitlist control groups only, the authors found a significantly larger effect size 
of .86. In our study, which also compares the intervention with a waitlist condition, we found 
even a larger effect for TBCT (d = 1.53). The mean effect size observed in studies that 
delivered the intervention only in individual format was .61, which additionally supports the 
efficacy of the TBCT in treating SAD symptoms. Moreover, the mean effect size of CBT 
treatment on depression measures was .70, and in our study we observed a larger effect size 
(d = 1.05), indicating that TBCT may be very effective in treating the depression symptoms 
associated with SAD condition. Finally, it is important to highlight that the authors found a 
mean effect size for social avoidance and distress measure of .70. We also found that TBCT 
was effective in reducing symptoms of social avoidance and distress, although with a larger 
effect size (d = 1.07) than previously found. 
 The results of this randomized clinical trial are consistent the TBCT literature as well 
(De Oliveira, 2008; De Oliveira et al., 2012; Delavechia et al., 2016), especially those related 
to SAD (De Oliveira et al., 2012b; Powell et al., 2013). In a recent trial that evaluated the 
effect of the main TBCT technique (the Trial) compared to conventional CBT techniques for 
generalized SAD, it was observed that the Trial was as effective as conventional CBT tools, 
with a large within-group effect size (d = 1.01 for the TBCT technique vs d = .83 for 
conventional CBT tools) (De Oliveira et al., 2012b; Powell et al., 2013). In our study, we also 
found a large within-group effect size for the social anxiety measure (d = 2.1), with a similar 
sample size and drop-out rates as previous studies.  
 Interestingly, results showed that comorbidity significantly moderated treatment 
efficacy. The individuals in the TBCT group with comorbid conditions evidenced greater 
reductions in social anxiety symptoms than those with SAD only, and were those most 
benefited by the treatment. These results indicate that TBCT may be effective not only in 
reducing social anxiety symptoms, but other comorbid conditions as well, especially 
depression. Alongside the large effect size found for TBCT on depression symptoms, results 
support TBCT as a promising intervention to treat not just SAD, but also the comorbid 
symptoms. This is an important finding as the presence of comorbidity in SAD is the rule 
rather than the exception. Clinicians that treat patients with SAD commonly have to deal with 
depression and other conditions associated with social anxiety. Thus, the presence of 
comorbidity in this clinical trial increases its external validity, and this study may be 
particularly helpful for researchers and clinicians that work in realistic clinical settings. 
 Although TBCT contains CBT techniques, such as psychoeducation, evaluation of 
automatic thoughts, and exposure, the main TBCT technique (the Trial) is a novel approach 
in the field designed to challenge and restructure dysfunctional CBs (de Oliveira, 2015a; de 
Oliveira et al., 2015b). The Trial is an emotional and experiential tool that the therapist uses 
to help the patients to evaluate their CBs through a role-play of a court trial. By playing the 
roles of prosecutor, defense attorney, juror, and defendant, the patients create a distance 
between themselves and their dysfunctional core beliefs, and get the opportunity to 
experience in session restructured and more realistic beliefs on an experiential level (de 
Oliveira, 2008; de Oliveira, 2012¹). Cognitive change is promoted through (metaphorically) 
challenging and deeply evaluating the CBs. Eventually, more constructive and positive core 
beliefs are developed and activated in the form of a lawsuit during the Trial (de Oliveira, 
2008; de Oliveira, 2012¹).  
 The systematic use of imagination and experiential exercises is one of the main 
distinctions between TBCT and other classic CBT. It is well-known that imagination can 
strongly evoke emotion, and literature argues that imagery can affect the behavior. Different 
therapeutic techniques have used imagery approaches to target dysfunctional behaviors, 
emotions, and beliefs (Holmes et al., 2016; Holmes, & Mathews, 2010). Thus, it is possible 
that the strong emotional benchmark involved in the Trial, and the continuous use of it in 
TBCT, leads patients to repeatedly imagine themselves behaving in a different way, which 
may elict more positive emotional states and promote cognitive restructuring.  
 It is possible that the promising results of this study may be attributed to the, as the 
individuals in the TBCT completed roleplay exercises involving a simulated court trial for 
seven sessions (the Trial was used from sessions 9 to 13, and the Trial II from sessions 14 to 
15). Patients may experience an improvement in different symptoms by imaging different 
descriptions of self. Studies that evaluated the effect of the Trial technique in various 
psychiatric disorders (De Oliveira, 2008; De Oliveira et al., 2012; Delavechia et al., 2016), 
and also in generalized SAD (De Oliveira et al., 2012b; Powell et al., 2013) show that this 
technique is effective in reducing the attachment to dysfunctional CBs and the associated 
emotional intensity, as well as social anxiety symptoms. However, further research is 
necessary to evaluate which components of the TBCT intervention are related to the decrease 
in social anxiety and depression symptoms, and which one may be the most effective 
approach in increasing the efficacy of the treatment of SAD.  
 The present study is not without limitations. The first one is related to significant 
baseline differences across the two conditions. Although the subjects were randomized by an 
independent researcher, the number of subjects in the experimental group with a prior SAD 
diagnosis and psychotropic medication at intake was higher than in the waitlist condition. 
Nevertheless, significant group differences emerged even after controlling for baseline 
differences.  
 The second limitation of this study concerns the control condition used. Research 
suggests that individuals with SAD randomized to waitlist condition exhibit small changes 
waiting for the intervention, and remain symptomatic after this period (Steinert, Stadter, 
Stark, & Leichsenring, 2016). Additionally, waitlist conditions have a larger effect size than 
studies that compare the treatment with placebo or treatment-as-usual control groups 
(Acarturk et al., 2009). Thus, the results obtained in the present study could be inflated given 
the adopted control condition. However, when compared with randomized clinical trials that 
evaluated the effect of CBT using waitlist conditions, the effect size of this study is even 
larger (Acarturk et al., 2009). Additionally, it is important to highlight that data based on 
effects of waitlist condition may be helpful as a benchmark in pilot studies that evaluate new 
treatments (Steinert, Stadter, Stark, & Leichsenring, 2016). This may make the waitlist 
condition in this study more appropriate, as this is the first randomized clinical trial that 
evaluated the effect of TBCT for generalized SAD. Thus, the results obtained at the present 
study may be useful for future TBCT research.  
 Another limitation is related to potential therapist effects, which has implications for 
evaluating the treatment outcome (Thompson, Cachelin, Striegel-Moore, Barton, Shea, & 
Wilson, 2012; Walwyn & Roberts, 2010). As only one therapist delivered the treatment in 
this study, it is not possible to evaluate therapist bias. However, there is a lower therapist 
effect when interventions follow a manual-based treatment or protocol, when therapists 
receive solid training in the intervention, and have a considerable clinical experience 
(Thompson, et al., 2012). In the current study, a manualized protocol was used, and the 
therapist received extensive training in the intervention.  
 Additionally, the reliance on self-report measures to assess primary outcomes might 
be a limitation. Self-report instruments are amenable to a number of response biases (e.g., 
social desirability, consistency seeking, etc.). Given that this is a pilot study, it was not 
feasible to use biological markers of anxiety (e.g., cortisol, heart rate variability, etc.), yet this 
will be an important future direction. Furthermore, it should be noted that prior research has 
indicated that self-report measures may be a more conservative estimate of treatment efficacy 
than clinician rated assessments (Cuijpers, Li, Hofmann, & Andersson, 2010). This could 
suggest that estimates of treatment efficacy were not overestimated in the current study.  
Finally, a further limitation of this study is the small sample size. Thus, the results 
must be interpreted as preliminary. Further research with a larger sample size and with active 
comparison conditions, such as conventional CBT, should be conducted to evaluate the effect 
of TBCT treating generalized SAD with comorbid disorders. 
 This study suggests that TBCT is effective in reducing social anxiety symptoms and 
depression symptoms, and it seems to be particularly efficacious in patients with comorbid 
conditions. TBCT may be a promising treatment for chronic GSAD patients that do not 
benefit from current CBT, especially those with comorbid condition. 
Footnotes 
 These analyses were re-conducted controlling for baseline differences. The effects of 
treatment condition on changes in symptoms of social anxiety and depression remained 
significant (g = -20.70, p < 0.01; g = -10.90, p < 0.01, respectively). 
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Figure 1.  
Flow diagram of participants’ progress through the study 
Figure  2.  
Conditional latent change score model for social anxiety 
Note: Intercepts and residuals are displayed. All path coefficients denote unstandardized 
estimates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1  
 
Participant Characteristics 
 
Table 2 
 
Differences between pre- and post-treatment 
 
Note: All p-values were submitted to false discovery rate correction. TBCT = Trial Based 
Cognitive Therapy; SD = Standard Deviation; d = Cohen’s d; * p < .05; **p < .01.  
 
Table 3.  
 
Freely estimated parameters of conditional latent change score model 
 
Note: aPre-Sx = intercept of pre-treatment social anxiety (or depression); aLCS = intercept of 
latent change score; fPreSx*LCS = covariance between pre-treatment depression and latent 
change score; fPreSx*PreSx = variance of pre-treatment social anxiety (or depression); fLCS*LCS = 
variance of latent change score; lExp = unstandardized path coefficient from experimental 
condition to the latent change score.  * p < .05; **p < .01.  
 
                                               
 
